Kytopen is at the forefront of advancing cell therapy manufacturing through its innovative non-viral gene delivery platform, Flowfect®. This technology is designed to enhance the efficiency of genome engineering by enabling rapid and scalable delivery of genetic materials such as mRNA, DNA, and CRISPR Cas9 RNP to billions of cells within minutes. By combining continuous fluid flow with electric fields, Flowfect® allows for unprecedented customization and predictive scaling, facilitating the transition from small-volume transfections to large-scale manufacturing. This capability not only accelerates drug discovery and optimization but also addresses the critical bottlenecks in biomanufacturing processes.

The Flowfect® platform includes two key products: Flowfect Discover™ and Flowfect TX™. Flowfect Discover™ is an automated small-volume liquid-handling system that supports high-throughput transfections, enabling researchers to test up to 96 conditions in a single experiment efficiently. In contrast, Flowfect TX™ is a closed-system transfection instrument designed for large-scale applications, capable of processing millions of cells rapidly while maintaining cell functionality. Together, these technologies empower researchers to optimize gene delivery parameters effectively, streamline the development of new therapeutic products, and ultimately expand patient access to next-generation living medicines.

United States

Kytopenis an MIT startup developing their proprietary FlowfectTM technology for non-viral delivery of molecules into hard-to-transfect immune cells.

Kytopen

Company Details